The Oncology Institute Reports Q3 Revenue Beat Amid GAAP EPS Miss
The Oncology Institute (STLN) reported third-quarter financial results characterized by a revenue beat and an improvement in adjusted EBITDA. The company posted revenue of $169.8 million, exceeding expectations by $1.11 million, though its GAAP earnings per share (EPS) of -$0.14 missed consensus estimates by $0.09. A significant highlight was the turnaround in Adjusted EBITDA, which reached a positive $3.4 million compared to a loss of $3.5 million in the prior period. As of September 30, 2026, the company reported cash and cash equivalents totaling $36.9 million.
Topics: cash flow earnings miss EBITDA improvement revenue beat